DK1024809T3 - Anvendelse af immunomodulatorer - Google Patents

Anvendelse af immunomodulatorer

Info

Publication number
DK1024809T3
DK1024809T3 DK98917808T DK98917808T DK1024809T3 DK 1024809 T3 DK1024809 T3 DK 1024809T3 DK 98917808 T DK98917808 T DK 98917808T DK 98917808 T DK98917808 T DK 98917808T DK 1024809 T3 DK1024809 T3 DK 1024809T3
Authority
DK
Denmark
Prior art keywords
immunomodulators
pka
well
pharmaceutical compositions
protein kinase
Prior art date
Application number
DK98917808T
Other languages
English (en)
Inventor
Einar Martin Aandahl
Fredrik Mueller
Vidar Hansson
Kjetil Tasken
Pael Aukrust
Stig Froeland
Bjoern S Skalhegg
Original Assignee
Lauras As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lauras As filed Critical Lauras As
Application granted granted Critical
Publication of DK1024809T3 publication Critical patent/DK1024809T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Stabilization Of Oscillater, Synchronisation, Frequency Synthesizers (AREA)
DK98917808T 1997-04-29 1998-04-29 Anvendelse af immunomodulatorer DK1024809T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO971997A NO971997D0 (no) 1997-04-29 1997-04-29 Bruk av immunmodulerende midler
PCT/NO1998/000134 WO1998048809A1 (en) 1997-04-29 1998-04-29 Use of immunomodulating agents

Publications (1)

Publication Number Publication Date
DK1024809T3 true DK1024809T3 (da) 2002-06-24

Family

ID=19900676

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98917808T DK1024809T3 (da) 1997-04-29 1998-04-29 Anvendelse af immunomodulatorer

Country Status (13)

Country Link
US (1) US20050250727A1 (da)
EP (1) EP1024809B1 (da)
JP (2) JP2002501499A (da)
AT (1) ATE213944T1 (da)
AU (1) AU738674B2 (da)
CA (1) CA2288215C (da)
DE (1) DE69804125T2 (da)
DK (1) DK1024809T3 (da)
ES (1) ES2171018T3 (da)
NO (1) NO971997D0 (da)
NZ (1) NZ501181A (da)
PT (1) PT1024809E (da)
WO (1) WO1998048809A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2333159A1 (en) * 1998-05-27 1999-12-02 Lauras As Method
AU772694B2 (en) * 1999-01-21 2004-05-06 Metamorphix International, Inc. Growth differentiation factor inhibitors and uses therefor
AU2080001A (en) * 1999-12-07 2001-06-18 University Of Medicine And Dentistry Of New Jersey Nucleic acid and protein expressed thereby and their involvement in stress
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
WO2005060996A2 (en) * 2003-12-23 2005-07-07 Lauras As Method of altering the pka type i signalling pathway
GB0413726D0 (en) 2004-06-18 2004-07-21 Lauras As Compounds
GB0421355D0 (en) * 2004-09-24 2004-10-27 Univ Oslo Inhibitors
GB0518027D0 (en) * 2005-09-05 2005-10-12 Birkeland Innovasjon As Compounds
GB0618235D0 (en) 2006-09-15 2006-10-25 Lauras As Process
CN113648323A (zh) 2013-06-05 2021-11-16 再生疗法有限公司 用于哺乳动物物种中诱导性组织再生的组合物和方法
US11078462B2 (en) 2014-02-18 2021-08-03 ReCyte Therapeutics, Inc. Perivascular stromal cells from primate pluripotent stem cells
US10240127B2 (en) 2014-07-03 2019-03-26 ReCyte Therapeutics, Inc. Exosomes from clonal progenitor cells
US20230285556A1 (en) * 2021-09-13 2023-09-14 Omeros Corporation Methods and compositions for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4568676A (en) * 1983-11-25 1986-02-04 Thomas Jefferson University Method of inhibiting aggregation using thromboxane synthetase inhibitor in combination with a cyclic AMP phosphodiesterase inhibitor
US5276017A (en) * 1990-09-14 1994-01-04 Trustees Of The University Of Pennsylvania Therapeutic and diagnostic applications of tropho-uteronectin (TUN) manipulation
US6429208B1 (en) * 1992-03-27 2002-08-06 Regents Of The University Of California Methods and compositions for restoring impaired cellular immune function
WO1993021929A1 (en) * 1992-05-01 1993-11-11 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Phosphorothioate derivatives of cyclic amp analogues
CA2154363A1 (en) * 1993-01-22 1994-08-04 Bruce A. Sullenger Localization of therapeutic agents
US5807693A (en) * 1994-11-23 1998-09-15 Icos Corporation Calcineurin inhibitory compounds and anchoring protein
US5795735A (en) * 1995-07-17 1998-08-18 Icos Corporation Isolated polynucleotides encoding PKA-binding proteins and methods of producing the proteins recombinantly
US5969117A (en) * 1995-08-17 1999-10-19 Hybridon, Inc. Modified protein kinase a-specific oligonucleotide

Also Published As

Publication number Publication date
DE69804125D1 (de) 2002-04-11
NO971997D0 (no) 1997-04-29
CA2288215A1 (en) 1998-11-05
JP2002501499A (ja) 2002-01-15
AU738674B2 (en) 2001-09-20
NZ501181A (en) 2002-03-01
AU7086598A (en) 1998-11-24
DE69804125T2 (de) 2002-10-31
JP2010111688A (ja) 2010-05-20
EP1024809A1 (en) 2000-08-09
CA2288215C (en) 2009-08-18
ATE213944T1 (de) 2002-03-15
PT1024809E (pt) 2002-07-31
EP1024809B1 (en) 2002-03-06
WO1998048809A1 (en) 1998-11-05
US20050250727A1 (en) 2005-11-10
ES2171018T3 (es) 2002-08-16

Similar Documents

Publication Publication Date Title
EA199900373A2 (ru) Фармацевтические композиции
ZA981627B (en) Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
DK1311269T3 (da) Fremgangsmåde til anvendelse af diketopiperaziner og sammensætning, som indeholder dem
DZ3191A1 (fr) Composés d'indazole et compositions pharmaceutiques inhibant les protéines kinases, et procédés d'utilisation de ceux-ci.
NO20006323D0 (no) Glykopeptidderivater og farmasöytiske sammensetninger som inneholder disse
TR200001218T2 (tr) İkameli karboksamidotiazoller, bunların üretimi ve bunları içeren farmasötik bileşimler.
AP9901478A0 (en) Compounds for the treatment of ischemia.
DK0912559T3 (da) Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
ATE215954T1 (de) Pyrazolo(4,3-d)pyrimidin-derivate und diese enthaltende pharmazeutische zubereitungen
EA200200571A1 (ru) Новая композиция и ее применение
BR9710372B1 (pt) composto, e, composiÇço farmacÊutica.
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
BR9915132A (pt) Método para inibir a atividade de quinase de proteìna, compostos da fórmula i e sais farmaceuticamente aceitáveis dos mesmos, uso do mesmo, e, composição farmacêutica.
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
DK0807111T3 (da) Substituerede heterocykliske forbindelser, fremgangsmåde til fremstillingen heraf samt farmaceutiske sammensætninger indeholdende disse
BR9810829B1 (pt) composto heterocìclico, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica.
DK1024809T3 (da) Anvendelse af immunomodulatorer
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
TR200001012T2 (tr) Yeni ariloksi-alkil-dialkilaminler.
DE10084671T1 (de) Pharmazeutische Zusammensetzungen
BRPI0407841A (pt) inibidores heterocìclicos de quinase
ATE387448T1 (de) 4,5-pyrazinoxindole als proteinkinasehemmer
NO20012727D0 (no) 3,4,5-trisubstituerte arylnitronforbindelser og farmasöytiske sammensetninger som inneholder samme
NO20014855D0 (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister